On July 29, 2026, Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NW Bio"), a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, reported to have entered into a $4.9 million convertible Promissory Note financing with YA II PN, Ltd., an investment fund managed by Yorkville Advisors Global, LP ("Yorkville"). The term of the Note is 12 months. No payments by the Company are due until maturity. The Note carries an Original Issue Discount of five percent but no interest. Repayment of all outstanding amounts is due at maturity. The Note includes customary default provisions. During the term of the Note, it is convertible at the option of the holder, at a small discount to the then prevailing market price. The Company plans to use the proceeds for general corporate purposes, including both its lead product and its in-licensed portfolios.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company and Yorkville also entered into a standby equity subscription agreement (the "Subscription Agreement") which the Company may use after the Note is repaid or converted. The prior standby equity subscription agreement was cancelled. Under this Subscription Agreement, NW Bio has the option, in its discretion, to require Yorkville to subscribe for up to $50 million of common shares in the Company at any time during the 24-month term of the Subscription Agreement at a small discount to the then prevailing market price, after the Note is repaid or converted. The Company has no obligation to make any such use of this arrangement, and the Company can cancel the arrangement at any time after the Note is repaid or converted. The Company has no current plans to draw upon this standby facility; however, the Company believes it will be useful to have this facility available for special funding needs in connection with certain key potential upcoming milestones.

Yorkville also acquired a warrant to purchase up to $2 million of shares at $0.205 per share pursuant to the above transaction.

(Filing, Northwest Biotherapeutics, JUL 29, 2026, View Source [SID1234669577])

On July 29, 2026 Perrigo Company plc (NYSE: PRGO), a leading provider of consumer self-care products, reported that Interim President and CEO Albert Manzone and CFO Eduardo Bezerra are scheduled to present at the Canaccord 46th Annual Growth Conference, on Wednesday, August 12th at 10:30 AM EDT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast can be accessed on the Perrigo website at View Source

(Press release, Perrigo Company, JUL 29, 2026, View Source [SID1234669494])

On July 29, 2026 Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, reported the successful initiation of its Phase 2/3 clinical trial of SIL204, the Company’s lead small interfering RNA (siRNA) product candidate, at Tel Aviv Sourasky Medical Center ("TASMC" or "Ichilov"), formally activating the first clinical site for the study in patients with locally advanced pancreatic cancer ("LAPC"). With the trial now initiated at TASMC, the site is cleared to commence patient screening.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The initiation on July 29, 2026 follows the receipt of all regulatory and institutional approvals required to open the site — including the Israeli Ministry of Health authorization received on March 24, 2026, and the institutional ethics approval previously granted by TASMC – and confirms that Silexion’s investigational medicinal product ("IMP") for SIL204 is available in Israel and positioned for the site upon initial patient screening. TASMC, commonly known as Ichilov, is one of Israel’s largest teaching hospitals and a leading center for oncology clinical research, and serves as the anchor site for the Israeli arm of Silexion’s Phase 2/3 program.

Within approximately four months, Silexion completed a rapid sequence of clinical readiness milestones for SIL204: the Israeli Ministry of Health approval received in March 2026; the initiation of GMP clinical supply manufacturing with Catalent announced in May 2026; TASMC’s own institutional ethics approval for the Phase 2/3 trial announced in May 2026; and the BfArM authorization in Germany received in June 2026, all of which culminated in the activation of TASMC as the first clinical site for the SIL204 program on July 29, 2026. With the first clinical site now formally active, Silexion’s SIL204 program is moving beyond the regulatory preparation phase and into active clinical execution, with additional Israeli and German sites progressing through activation in parallel and first patient dosing anticipated as the next milestone.

"Successfully initiating our first clinical site at Tel Aviv Sourasky Medical Center is a defining operational milestone for Silexion and for the SIL204 program," said Ilan Hadar, Chairman and Chief Executive Officer of Silexion Therapeutics. "This is the moment where years of preclinical development, GMP manufacturing scale-up, and multi-jurisdictional regulatory work have translated into an active clinical program. TASMC is one of Israel’s premier oncology research centers and having it as our first active site provides an exceptional foundation as we bring additional Israeli and German centers online in the weeks and months ahead. We look forward to advancing rapidly toward first patient dosing."

The Phase 2/3 trial is designed to evaluate SIL204 in combination with standard-of-care chemotherapy in patients with locally advanced pancreatic cancer, using Silexion’s innovative dual-route administration strategy— combining intratumoral delivery designed to overcome the stromal barrier that can limit systemic drug penetration into the primary tumor, alongside systemic administration to address metastatic disease. The study is structured as an initial safety run-in cohort of approximately 18 patients, followed by expansion into sites worldwide to obtain a randomized cohort of approximately 166 patients. Additional Israeli sites, alongside leading German oncology centers approved under the EU Clinical Trials Regulation framework, are advancing through site activation and are expected to join the program in the coming months.

SIL204, which is designed to silence a broad range of KRAS mutations rather than a single variant, supports Silexion’s potential applicability across multiple high-value cancer indications beyond pancreatic cancer. KRAS mutations are present in approximately 90% of pancreatic cancers, 45% of colorectal cancers, and 30–35% of lung adenocarcinomas, representing one of the largest and most persistent unmet needs in oncology. Pancreatic cancer—which is the subject of the current, initial clinical trial— remains one of the most lethal malignancies, with a five-year survival rate below 13%, and more than 80% of pancreatic cancer mortality driven by metastatic disease.

(Press release, Silexion Therapeutics, JUL 29, 2026, View Source [SID1234669512])

On July 28, 2026 GSK plc (LSE/NYSE: GSK) licensor Hansoh Pharmaceutical Group Co., Ltd. reported that ARTEMIS-011, its pivotal phase III trial evaluating risvutatug rezetecan (Ris-Rez) in patients with osteosarcoma who have progressed or relapsed after receiving at least two prior lines of systemic therapy, met its primary endpoint of progression-free survival (PFS).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In the trial, conducted in patients in China, Ris-Rez, a B7-H3-targeted antibody-drug conjugate (ADC), demonstrated statistically significant and clinically meaningful improvements in PFS compared with chemotherapy. Consistent benefit was also observed across secondary endpoints, including overall survival. The safety profile of ARTEMIS-011 is consistent with prior findings in this tumour type, and no new safety signals were identified. These data will be used by Hansoh Pharma for regulatory submission in China.

GSK is advancing EMBOLD Sarcoma-202, a global phase Ib/II trial of Ris-Rez in previously treated unresectable advanced or metastatic sarcomas, including osteosarcoma. The study is part of GSK’s broader clinical development programme across multiple solid tumours, including lung and prostate cancers, under its exclusive global rights to develop Ris-Rez outside mainland China, Hong Kong, Macau and Taiwan. Ris-Rez has US FDA Breakthrough Therapy Designation in relapsed or refractory osteosarcoma.

Today’s results from Hansoh follow recently reported pivotal data in advanced or relapsed small-cell lung cancer (SCLC), making Ris-Rez the only B7-H3-targeted ADC to deliver positive phase III outcomes across multiple tumour types.

Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK said: "Building on recent pivotal data in small-cell lung cancer, these results strengthen our confidence in the broad potential of Ris-Rez and validate B7-H3 as a promising target across multiple tumour types."

Osteosarcoma mainly affects children and young adults and is the most common primary bone cancer, accounting for 20-40% of all bone cancers1. It is a rare bone cancer with a global incidence of approximately 3.4 cases per million people per year2. Following first-line chemotherapy, treatment options for patients with relapsed osteosarcoma are severely limited, with no clear standard of care available3. After patients progress on two prior lines of treatment, options become even more limited, with no approved therapies.

About risvutatug rezetecan
Ris-Rez is a novel investigational B7-H3-targeted ADC composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload. GSK acquired exclusive worldwide rights (excluding China’s mainland, Hong Kong, Macau, and Taiwan) from Hansoh Pharma to progress clinical development and commercialisation of Ris-Rez.

Regulatory designations received for Ris-Rez to date include orphan drug designations from the US Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare in SCLC and the European Medicines Agency (EMA) in a category of cancer that includes SCLC, called pulmonary neuroendocrine carcinoma; Priority Medicines (PRIME) Designation from the EMA for relapsed or refractory extensive-stage SCLC (ES-SCLC); and Breakthrough Therapy Designations for relapsed or refractory ES-SCLC and relapsed or refractory osteosarcoma from the US FDA.

(Press release, GlaxoSmithKline, JUL 28, 2026, View Source [SID1234669457])

On July 28, 2026 PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, reported that management will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, at 9:00 AM ET in Boston, Massachusetts.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the event can be accessed at the company’s investors page at investor.pacificbiosciences.com. A replay of the webcast will be available for at least 30 days following the event.

(Press release, Pacific Biosciences, JUL 28, 2026, View Source [SID1234669474])